NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

BridgeBio Pharma, Inc. (BBIO) Stock Analysis

BridgeBio Pharma, Inc. (BBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

BBIO

$74.84

−$0.57 (−0.76%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BBIO with… →

BBIO Key Statistics

As of Sep 4, 2026
Trading
Open
$74.98
Previous Close
$75.41
Day's Range
74.11–75.37
52-Week Range
48.78–93.42
Volume
1.54M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.97
Valuation
Market Cap
$14.63B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
20.52
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.53
Financials (FY)
Revenue (FY)
$502.08M+126.26%
Net Income (FY)
−$724.93M
Profit marginThe share of revenue left as profit after all costs and taxes.
−97.03%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
195.49M
1-Year Return
+44.40%
Dividend and dates
Earnings Date
October 28, 2026estimated
Avg Volume
3.04M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BBIO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−2.16%
2025+178.75%
2024−32.03%
2023+429.79%
2022−54.32%
2021−76.54%
2020+102.88%
2019 (partial year)+27.22%

As of September 4, 2026.

BBIO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$502.08M−$724.93M−144.4%
2024$221.90M−$535.76M−241.4%
2023$9.30M−$643.20M−6913.9%
2022$77.65M−$481.18M−619.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$502.08M$481.11M−$502.06M−$724.93M−144.4%
2024$221.90M$218.02M−$577.37M−$535.76M−241.4%
2023$9.30M$6.86M−$599.44M−$643.20M−6913.9%
2022$77.65M$74.21M−$468.44M−$481.18M−619.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BBIO Valuation vs Biotechnology Median

Median of 656 stocks
MetricBBIOBiotechnology medianvs median
P/S ratio20.5215.2634% above
Profit margin−97.03%0.00%97.0 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values BridgeBio Pharma, Inc. (BBIO) at $14.63B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 999.

Over the past 52 weeks the price has ranged from $48.78 to $93.42. The most recent close on file for BBIO is $74.84, dated September 4, 2026. That is −$0.57 (−0.76%) against the previous close. The latest close sits 53.42% above that 52-week low.

Financial Health

In fiscal 2025, BridgeBio Pharma, Inc. reported revenue of $502.08M. Against the prior fiscal year total of $221.90M, that is a change of +126.26%. The same year closed with a net loss of $724.93M. Profit margin runs at −97.03%. That is 97 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −3.53.

Across the 4 fiscal years on file, revenue moves from $77.65M in 2022 to $502.08M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 20.52 times revenue. On price-to-sales that is 34.42% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 0.97. Daily returns over the trailing 7 years annualize to a volatility of 83.09%. Over the trailing twelve months the price has returned +44.40%. Across 5 years the annualized return works out at +7.71%.

Growth & Income

No dividend is on file for BBIO.

So far in 2026 the price is −2.16%. Across the complete calendar years on file, 2023 returned +429.79% and 2021 returned −76.54%. Of the 6 complete calendar years on file, 3 finished higher.

Peer Comparison

BridgeBio Pharma, Inc. (BBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BridgeBio Pharma, Inc. BBIO $14.63B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. BridgeBio Pharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

Visit website →